About: Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120
Creator	Deng, Hongkui Ding, Mingxiao Jiang, Pengfei Luo, Min Nie, Yuchun Aihua, Zheng Liu, Yanxia Liyin, Du Yin, Xiaolei Yuan, Fei
topic	covid:323224516c54360774946c8597b50bd54a4d9e0d#this
Source	Elsevier; Medline; PMC
abstract	Abstract Recombinant viral vectors are useful tools for AIDS vaccine development. However, expression of HIV-1 envelope genes using viral vectors has not been successful in the induction of potent neutralizing antibodies in vivo. We took advantage of the strong immunogenicity of vesicular stomatitis virus (VSV)-based vector and expressed HIV-1 HXB2 gp120 gene in the recombinant VSV. Our results showed that HIV-1 gp120 protein expressed by the recombinant VSV retained the native conformation of the protein to some degree and was recognized by two well-characterized broad anti-HIV-1 neutralizing monoclonal antibodies b12, 2G12. We further showed that only one time intranasal immunization with the recombinant VSV led to production of anti-HIV-1 anti-sera in mice. In addition, we found that the anti-sera had the ability to neutralize not only HXB2 envelope-pseudotyped HIV-1 viruses but also HIV-1 pseudotyped viruses with JRFL envelopes. These results suggest that HIV-1 gp120 expressed by the recombinant VSV, in combination with the route of intranasal administration, is an effective strategy to evaluate the immunogenicity of HIV-1 envelope protein and its variants in mice.
has issue date	2006-01-13(xsd:dateTime)
bibo:doi	10.1016/j.bbrc.2005.11.067
bibo:pmid	16313884
has license	els-covid
sha1sum (hex)	323224516c54360774946c8597b50bd54a4d9e0d
schema:url	https://doi.org/10.1016/j.bbrc.2005.11.067
resource representing a document's title	Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120
has PubMed Central identifier	PMC7092882
has PubMed identifier	16313884
schema:publication	Biochemical and Biophysical Research Communications
resource representing a document's body	covid:323224516c54360774946c8597b50bd54a4d9e0d#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/323224516c54360774946c8597b50bd54a4d9e0d
is schema:about of	named entity 'INTRANASAL ADMINISTRATION' named entity 'COMBINATION' named entity 'ENVELOPE PROTEIN' named entity 'THESE' named entity 'EFFECTIVE' named entity 'ANTI-HIV' named entity 'SUCCESSFUL' named entity 'RECOMBINANT' named entity 'SUGGEST' named entity 'GP120' named entity 'CHARACTERIZED' named entity 'VECTOR' named entity 'VIRAL VECTORS' named entity 'NATIVE CONFORMATION' named entity 'TOOLS' named entity 'ADVANTAGE' named entity 'STRATEGY' named entity 'AIDS VACCINE' named entity 'vaccine' named entity 'However' named entity 'VSV' named entity 'intranasal administration' named entity 'HIV-1' named entity 'potent' named entity 'VESICULAR STOMATITIS VIRUS' named entity 'NEUTRALIZING ANTIBODIES' named entity 'GP120' named entity 'ITS' named entity 'ENVELOPE' named entity 'EXPRESSED' named entity 'INDUCTION' named entity 'NEUTRALIZING ANTIBODIES' named entity 'VIRUSES' named entity 'VARIANTS' named entity 'MONOCLONAL ANTIBODIES' named entity 'BUT' named entity 'EVALUATE' named entity 'RESULTS' named entity 'SERA' named entity 'RECOMBINANT' named entity 'ADDITION' named entity 'ANTISERA' named entity 'EXPRESSION' named entity 'RETAINED' named entity 'OUR' named entity 'VACCINE DEVELOPMENT' named entity 'B12' named entity 'INTRANASAL IMMUNIZATION' named entity 'FOUND' named entity 'IN VIVO' named entity 'PROTEIN ' named entity 'INTRANASAL ADMINISTRATION' named entity 'GENES' named entity 'HUMAN IMMUNODEFICIENCY VIRUS TYPE 1' named entity 'BROAD' named entity 'LED' named entity 'USEFUL' named entity 'ROUTE' named entity 'BASED' named entity 'DEGREE' named entity 'IMMUNOGENICITY' named entity 'STRONG' named entity 'HIV-1' named entity 'MICE' named entity 'GENE' named entity 'USING' named entity 'PRODUCTION' named entity 'VESICULAR STOMATITIS VIRUS' covid:arg/323224516c54360774946c8597b50bd54a4d9e0d named entity 'protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software